Fig. 5: Outcomes following the development of therapy-related clonal cytopenia (t-CC). | Blood Cancer Journal

Fig. 5: Outcomes following the development of therapy-related clonal cytopenia (t-CC).

From: Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms

Fig. 5

(i) Progression-free survival (PFS), and (ii) overall survival (OS) of the entire AQ11 cohort. (iii) PFS and (iv) OS stratified by the presence of abnormal cytogenetics.(v) PFS and OS (vi) stratified by the presence of pathogenic variants in DNTM3A, TET2, or ASXL1 (DTA) genes. Abnl abnormal, cyto. cytogenetics, DTA DNMT3A, TET2, and ASXL1 genes, PV pathogenic variant, NR not reached.

Back to article page